PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Recursion Pharmaceuticals, Inc. (RXRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US75629V1044

CUSIP

75629V104

Sector

Healthcare

IPO Date

Apr 16, 2021

Highlights

Market Cap

$1.80B

EPS (TTM)

-$1.54

Total Revenue (TTM)

$65.18M

Gross Profit (TTM)

$1.96M

EBITDA (TTM)

-$366.27M

Year Range

$5.70 - $15.74

Target Price

$9.86

Short %

24.56%

Short Ratio

14.80

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
RXRX vs. ROIV RXRX vs. GSK RXRX vs. RLAY RXRX vs. VIR RXRX vs. XBI RXRX vs. MSFT RXRX vs. META RXRX vs. INTU RXRX vs. CRSP RXRX vs. IBB
Popular comparisons:
RXRX vs. ROIV RXRX vs. GSK RXRX vs. RLAY RXRX vs. VIR RXRX vs. XBI RXRX vs. MSFT RXRX vs. META RXRX vs. INTU RXRX vs. CRSP RXRX vs. IBB

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Recursion Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%JuneJulyAugustSeptemberOctoberNovember
-81.79%
42.62%
RXRX (Recursion Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Recursion Pharmaceuticals, Inc. had a return of -42.19% year-to-date (YTD) and -15.93% in the last 12 months.


RXRX

YTD

-42.19%

1M

-9.95%

6M

-37.77%

1Y

-15.93%

5Y (annualized)

N/A

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

25.15%

1M

2.74%

6M

12.53%

1Y

30.93%

5Y (annualized)

13.79%

10Y (annualized)

11.18%

Monthly Returns

The table below presents the monthly returns of RXRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-4.56%43.04%-25.93%-21.56%5.88%-9.42%9.33%-11.22%-9.48%-4.10%-42.19%
20238.04%-2.16%-18.16%-28.49%83.86%-14.82%89.02%-38.39%-12.07%-30.98%29.73%43.94%27.89%
2022-30.88%-7.52%-34.61%-13.41%-1.29%33.01%3.93%24.23%1.24%-0.85%-10.90%-17.98%-54.99%
20216.71%-21.08%38.47%-16.85%-16.90%-8.76%-16.78%-0.16%-10.41%-45.27%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of RXRX is 35, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of RXRX is 3535
Combined Rank
The Sharpe Ratio Rank of RXRX is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 3636
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 3535
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 3333
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 3636
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for RXRX, currently valued at -0.19, compared to the broader market-4.00-2.000.002.004.00-0.192.53
The chart of Sortino ratio for RXRX, currently valued at 0.29, compared to the broader market-4.00-2.000.002.004.000.293.39
The chart of Omega ratio for RXRX, currently valued at 1.03, compared to the broader market0.501.001.502.001.031.47
The chart of Calmar ratio for RXRX, currently valued at -0.18, compared to the broader market0.002.004.006.00-0.183.65
The chart of Martin ratio for RXRX, currently valued at -0.37, compared to the broader market0.0010.0020.0030.00-0.3716.21
RXRX
^GSPC

The current Recursion Pharmaceuticals, Inc. Sharpe ratio is -0.19. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Recursion Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.19
2.53
RXRX (Recursion Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Recursion Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-86.21%
-0.53%
RXRX (Recursion Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Recursion Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Recursion Pharmaceuticals, Inc. was 88.97%, occurring on May 2, 2023. The portfolio has not yet recovered.

The current Recursion Pharmaceuticals, Inc. drawdown is 86.21%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-88.97%Jul 14, 2021454May 2, 2023
-38.1%Apr 30, 202110May 13, 202124Jun 17, 202134
-10.54%Apr 19, 20211Apr 19, 20212Apr 21, 20213
-10.45%Jun 22, 20212Jun 23, 20218Jul 6, 202110
-8.29%Apr 22, 20212Apr 23, 20214Apr 29, 20216

Volatility

Volatility Chart

The current Recursion Pharmaceuticals, Inc. volatility is 21.24%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%JuneJulyAugustSeptemberOctoberNovember
21.24%
3.97%
RXRX (Recursion Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Recursion Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Recursion Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items